Navigation Links
Orchid Cellmark Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/6/2008

sitively impacted our net results.

At December 31, 2007, cash and cash equivalents were $20.9 million and restricted cash was $958 thousand. In the fourth quarter of 2007, cash provided by operations was $1.9 million and cash used for capital expenditures was $61 thousand. In the fourth quarter of 2007, Orchid Cellmark completed the acquisition of ReliaGene, a provider of forensic and paternity DNA testing services based in New Orleans, Louisiana. The net aggregate purchase price was $5.4 million in cash and 560,539 shares of Orchid Cellmark common stock (valued at $2.9 million). As a result of the ReliaGene acquisition, Orchid Cellmark assumed $240 thousand of short-term and $525 thousand of long-term debt, of which $188 thousand is current, as of December 31, 2007.

Orchid Cellmark recently was awarded a significant portion of the work that it bid for in the North West/South West and Wales regional tender (internally referred to as the mega tender) primarily for DNA related work. The award followed a lengthy competitive bidding process. Under the award, Orchid Cellmark will provide forensic services for several police forces from this region and will carry out DNA testing of database crime scene samples, forensic casework and PACE samples (DNA database under the Police and Criminal Evidence Act). It is anticipated that work from this award will commence in the second quarter of 2008 after the completion of contracts with each of the police forces. Also in the U.K., as previously reported, Orchid Cellmark performs forensic testing services for several police forces in the U.K. through an arrangement with LGC, the successor to Forensic Alliance Ltd. The agreement with LGC was terminated effective July 15, 2007, and although Orchid Cellmark has been continuing to provide its services through subcontract extension agreements, LGC will likely seek to provide DNA services directly to two key police forces in the U.K. that are presently serviced by Orchid Ce
'/>"/>

SOURCE Orchid Cellmark Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine news :

1. Orchid Cellmark to Announce Fourth Quarter and Full Year 2007 Financial Results on March 6, 2008
2. Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
3. Orchid Cellmark Reports Third Quarter 2007 Financial Results
4. MDS Reports First Quarter 2008 Results
5. American Oriental Bioengineering Reports Fourth Quarter and Full Year 2007 Financial Results
6. Longs Drug Stores Corporation Reports Results for Fourth Quarter and Fiscal Year 2008
7. LeMaitre Vascular Reports Q4 2007 Revenue of $11.1 Million, a 27% Increase
8. MannKind Corporation Reports Fourth Quarter and Full Year 2007 Financial Results
9. Simcere Pharmaceutical Group Reports Unaudited Fourth Quarter and Fiscal Year 2007 Results
10. Endocare Reports 2007 Annual and Fourth Quarter Financial Results
11. Folic Acid in the Food Supply Reduces Birth Defects, but May Cause Extra Cancers, Reports the Harvard Womens Health Watch
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... brain structure could help predict how willing you are to ... Yale University found those with greater volume in a part ... more likely to engage in risky behavior than people with ... by the U.S. National Institute on Aging, involved two groups ... The researchers sought to determine how brain structure influences risk ...
(Date:9/19/2014)... News) -- Although there is mounting evidence that ... and older adults in the United States don,t ... new research. Less than one-quarter of adults ... the Department of Health and Human Services, the ... promoting health and fitness and staying independent, researchers ...
(Date:9/19/2014)... Alan Mozes HealthDay Reporter ... Cancer patients burdened by stress and family conflicts before ... their operation, a new study suggests. Investigators found ... have a nearly three times greater risk for complications ... of life. "We,ve long known that patient quality ...
(Date:9/19/2014)... 2014 Lipitor lawsuits ( http://www.thelipitorlawsuit.com/ ... to develop Type 2 diabetes continue to move forward ... District Court, District of South Carolina, Bernstein Liebhard LLP ... 12, 2014, discovery is underway and moving forward in ... Pfizer, Inc., the manufacturer of Lipitor, has produced millions ...
Breaking Medicine News(10 mins):Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 2Health News:Lipitor Lawsuits Move Forward, as Discovery Proceeds in Federal Multidistrict Litigation, Bernstein Liebhard LLP Reports 3
... ATLANTA, Feb. 3 Brent McKenzie, based ... Consulting, the nation,s fastest growing,pharmacy benefit firm, ... Mr. McKenzie offers his clients over ... Benefits and Pharmacy Benefit Management arena.,Brent has ...
... Cancer Care Access, Efficiency and Quality; Created Based ... 3 /PRNewswire-USNewswire/ -- The National Policy ... the nation,s largest cancer treatment and research networks ... Principles for Reforming Cancer Care, designed to guide ...
... of medical research, study finds , , TUESDAY, Feb. 3 ... white parents to distrust medical research, which may explain ... So conclude University of Pittsburgh researchers who surveyed 190 ... to a primary-care clinic. , The parents were asked ...
... 2009) Green tea products have become regarded as a ... its benefit against a variety of diseases, including cancer. ... tea may counteract the anticancer effects of one cancer ... contraindicated for patients taking this medicine to ensure its ...
... study suggests that Capn4, a protein involved in cell ... after liver transplantation. Capn4 could potentially be used as ... These findings are in the February issue of ... Sons on behalf of the American Association for the ...
... popular assumptions about the health benefits of green tea, ... found that the widely used supplement renders a cancer ... lymphoma completely ineffective in treating cancer. , The ... extract (GTE) called EGCG destroys any anticancer activity of ...
Cached Medicine News:Health News:Brent McKenzie Joins ARMSRx Pharmacy Benefit Consulting 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 2Health News:US Oncology Adopts Principles for Reforming Cancer Care 3Health News:Parental Distrust May Explain Lack of Black Children in Clinical Trials 2Health News:Green tea may negate the effects of a common cancer therapy 2Health News:Green tea may negate the effects of a common cancer therapy 3Health News:Protein predicts liver cancer recurrence and after transplantation 2Health News:USC study finds that green tea blocks benefits of cancer drug 2
(Date:9/19/2014)... -- According to market research report, ... & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, Surgical Procedure, ... Geography - Global Trends & Forecast to 2019", ... market on the basis of various types, applications, ... market size of each of these segments in ...
(Date:9/19/2014)... , Sept. 19, 2014  Lpath, Inc. ... in bioactive lipid-targeted therapeutics, announced today that it ... registered shares of common stock and 3,605,042 unregistered ... purchase price for one registered share of common ... unregistered share of common stock will be $3.475.  ...
(Date:9/19/2014)... September 19, 2014 Aufgrund ... den äußerst erfolgreichen Serialisierungs-Countdown-Kalender aktualisiert, der jetzt auch ... PDF, verfügbar unter pharmaserialisation.com , zeigt die ... jeweils in Kraft treten. Für international ... länger um das "ob", sondern darum, "wann" sie ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3Lpath, Inc. Announces $12.5 Million Registered Direct Offering 2Lpath, Inc. Announces $12.5 Million Registered Direct Offering 3Pharma IQ stellt weltweite Serialisierungsfristen in seinen Countdown-Kalender 2014 - 2018 2
...
A modular concept consisting of two J-Arms, to be fixed at any position of the skull clamp, allowing to the surgeon an unobstructed access to the surgical field....
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
Iowa University periosteal elevator, blade width 11/16" (17 mm), length 7 1/4" (184 mm)....
Medicine Products: